$7.14
5.47% today
Nasdaq, Apr 01, 05:42 pm CET
ISIN
US0050831009
Symbol
ACTU
Sector
Industry

Actuate Therapeutics Stock price

$6.77
-0.47 6.49% 1M
-0.68 9.13% 6M
-1.19 14.95% YTD
-1.23 15.38% 1Y
-1.23 15.38% 3Y
-1.23 15.38% 5Y
-1.23 15.38% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-1.13 14.30%
ISIN
US0050831009
Symbol
ACTU
Sector
Industry

Key metrics

Market capitalization $132.23m
Enterprise Value $123.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1,270.17
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-25.16m
Free Cash Flow (TTM) Free Cash Flow $-21.84m
Cash position $8.64m
EPS (TTM) EPS $-1.41
Show more

Is Actuate Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Actuate Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Actuate Therapeutics forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Actuate Therapeutics forecast:

Buy
100%

Financial data from Actuate Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.48 6.48
-
-
- Research and Development Expense 19 19
-
-
-25 -25
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -25 -25
-
-
Net Profit -27 -27
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Actuate Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Actuate Therapeutics Stock News

Neutral
GlobeNewsWire
about 2 months ago
CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief E...
Neutral
GlobeNewsWire
4 months ago
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced new positive data from its ongoing and f...
Neutral
GlobeNewsWire
5 months ago
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “ Webinar Wednesd...

Company Profile

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Head office United States
CEO Daniel Schmitt
Employees 10
Website www.actuatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today